Aberdeen Group
KNSA icon

Aberdeen Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Aberdeen Group’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.8M Buy
403,485
+29,851
+8% +$1.55M 0.04% 373
2026
Q1 		$18M Sell
373,634
-26,964
-7% -$1.19M 0.03% 454
2025
Q4 		$16.5M Buy
400,598
+241,876
+152% +$9.7M 0.03% 491
2025
Q3 		$6.16M Buy
+158,722
New +$5.16M 0.01% 677

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Aberdeen Group's KNSA Position: Q2 2026 in Review

Aberdeen Group increased its Kiniksa Pharmaceuticals (KNSA) stake by 8% in Q2 2026, buying an estimated $1.55M and bringing the position to 403,485 shares worth $25.8M. The position accounts for 0.04% of the portfolio, ranked #373.

Aberdeen Group first reported a position in KNSA in Q3 2025 and has held it in 4 quarters since. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Aberdeen Group held 403,485 shares of Kiniksa Pharmaceuticals worth $25.8M as of Q2 2026.
  • Aberdeen Group bought 29,851 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $1.55M.
  • Kiniksa Pharmaceuticals made up 0.04% of Aberdeen Group's portfolio in Q2 2026, its #373 holding.
  • Aberdeen Group first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.